Search Results - "Kopetz S"

36P BREAKWATER: Post-hoc subgroup efficacy analyses by chemotherapy ± bevacizumab regimens vs encorafenib plus cetuximab + mFOLFOX6.

Authors: Yoshino, T. Kopetz, S. Van Cutsem, E. et al.

Source: Annals of Oncology. 2025 Supplement 1, Vol. 36, pS21-S22. 2p.

Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with RAS mutation status.

Authors: Kawaguchi, Y. Kopetz, S. Cao, H. S. Tran et al.

Source: British Journal of Surgery. Aug2021, Vol. 108 Issue 8, p968-975. 8p.

A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer.

Authors: Hoff, P. M. Kopetz, S. Thomas, M. B. et al.

Source: British Journal of Cancer. 9/2/2008, Vol. 99 Issue 5, p722-726. 5p. 4 Charts.

962P Precemtabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer: Updated clinical data from the phase I PROCEADE-CRC-01 study.

Authors: Kopetz, S. Garcia-Carbonero, R. Han, S-W. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS629-S629. 1p.

729MO Circulating tumour (ct) DNA analysis of BRAF V600E dynamics and changes in genomic landscape in patients (pts) with first-line (1L) BRAF V600E-mutant metastatic colorectal cancer (mCRC) treated in BREAKWATER.

Authors: Kopetz, S. Shah, K. Yoshino, T. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS510-S510. 1p.

Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer.

Authors: Kopetz, S. Grothey, A. Yaeger, R. et al.

Source: New England Journal of Medicine. 10/24/2019, Vol. 381 Issue 17, p1632-1643. 12p.

573P M9140, an anti-CEACAM5 antibody drug conjugate (ADC), in patients with metastatic colorectal cancer (mCRC): Updated results from a phase I trial.

Authors: Boni, V. Kopetz, S. Kato, K. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS466-S466. 1p.

Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.

Authors: Brudvik, K. W. Kopetz, S. E. Li, L. et al.

Source: British Journal of Surgery. Sep2015, Vol. 102 Issue 10, p1175-1183. 9p.

316O Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study.

Authors: Kopetz, S. Murphy, D.A. Pu, J. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS681-S682. 2p.

Metastasis of cancer: when and how?

Authors: Lee, W.-C. Kopetz, S. Wistuba, I. I. et al.

Source: Annals of Oncology. Sep2017, Vol. 28 Issue 9, p2045-2047. 3p.

SO-11 KISIMA-01 trial: Safety, tolerability and immunogenicity of ATP128 with or without ezabenlimab (BI 754091) in patients with stage IV colorectal cancer – preliminary results from a phase 1b study.

Authors: Kopetz, S. Prenen, H. Sharma, S. et al.

Source: Annals of Oncology. 2021 Supplement 3, Vol. 32, pS206-S207. 2p.

KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary.

Authors: Vauthey, J.-N. Kopetz, S. Aloia, T. A. et al.

Source: British Journal of Cancer. 10/9/2012, Vol. 107 Issue 8, p1442-1443. 2p.

366P The PLK1 inhibitor onvansertib overcomes irinotecan resistance in RAS-mutated (mRAS) metastatic colorectal cancer (mCRC) in vivo and in patients (pts).

Authors: Kopetz, S. Ridinger, M. Sorokin, A. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS704-S704. 1p.

Perioperative chemotherapy for resectable hepatic metastases.

Authors: Kopetz S Vauthey JN

Source: Lancet. 3/22/2008, Vol. 371 Issue 9617, p963-965. 3p.

SO-28 Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib + cetuximab +/- binimetinib in BEACON CRC.

Authors: Aderka, D. Kopetz, S. Grothey, A. et al.

Source: Annals of Oncology. 2021 Supplement 3, Vol. 32, pS214-S214. 1p.

Environmental stability of PDMS-waveguides for electrical-optical circuit boards.

Authors: Zhu, D. Cai, D. Kopetz, S. et al.

Source: Electronics Letters (Institution of Engineering & Technology); 5/24/2007, Vol. 43 Issue 11, p627-629, 3p, 1 Diagram, 1 Chart, 2 Graphs

LBA-7 Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC.

Authors: Grothey, A. Kopetz, S. Yaeger, R. et al.

Source: Annals of Oncology. 2020 Supplement 3, Vol. 31, pS243-S243. 1p.

LBA-006 - BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer.

Authors: Kopetz, S. Grothey, A. Van Cutsem, E. et al.

Source: Annals of Oncology. 2019 Supplement, Vol. 30, piv154-iv154. 1p.

High-temperature stable flexible polymer waveguide laminates.

Authors: Kopetz, S. Rabe, E. Neyer, A.

Source: Electronics Letters (Institution of Engineering & Technology). 5/25/2006, Vol. 42 Issue 11, p634-635. 2p. 2 Black and White Photographs, 1 Diagram, 1 Graph.

Subjects: Polymers, Optical communications, Waveguides, Polychlorinated biphenyls, Temperature

Polysiloxane optical waveguide layer integrated in printed circuit board.

Authors: Kopetz, S. Rabe, E. Kang, W.J. et al.

Source: Electronics Letters (Institution of Engineering & Technology). 5/27/2004, Vol. 40 Issue 11, p668-669. 2p.

Subjects: Waveguides, Printed circuits, Siloxanes, Optoelectronics, Electric circuits